PTJ
BMRN icon

Paul Tudor Jones’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paul Tudor Jones’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Buy
9,200
+3,800
+70% +$208K ﹤0.01% 2796
2026
Q1 		$305K Sell
5,400
-24,600
-82% -$1.43M ﹤0.01% 3126
2025
Q4 		$1.78M Sell
30,000
-18,900
-39% -$1.03M ﹤0.01% 1890
2025
Q3 		$2.65M Sell
48,900
-800
-2% -$45.8K ﹤0.01% 1626
2025
Q2 		$2.73M Buy
49,700
+26,900
+118% +$1.58M 0.01% 1451
2025
Q1 		$1.61M Buy
22,800
+8,700
+62% +$585K 0.01% 1490
2024
Q4 		$927K Buy
14,100
+1,100
+8% +$73.7K ﹤0.01% 1781
2024
Q3 		$914K Buy
+13,000
New +$1.09M ﹤0.01% 1678

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Paul Tudor Jones's BMRN Position: Q1 2026 in Review

Paul Tudor Jones sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 105,523 shares — an estimated $6.15M sold.

Paul Tudor Jones first reported a position in BMRN in Q3 2014 and held it in 23 quarters. The position peaked at $6.55M in Q4 2024. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Paul Tudor Jones reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 105,523 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $6.15M.
  • Paul Tudor Jones first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 23 quarters.
  • Paul Tudor Jones's BioMarin Pharmaceuticals position peaked at $6.55M in Q4 2024.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.